“Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine 6, no. 2 (March 4, 2022): s4. Accessed July 22, 2025. https://skin.dermsquared.com/skin/article/view/1520.